

Frans Rutten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11188992/publications.pdf>

Version: 2024-02-01

17
papers

900
citations

759233

12
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1239
citing authors

#	ARTICLE	IF	CITATIONS
1	Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2009, 12, 409-418.	0.3	395
2	The role of economic evaluation in the pricing and reimbursement of medicines. <i>Health Policy</i> , 1997, 40, 199-215.	3.0	105
3	What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?. <i>Value in Health</i> , 2010, 13, 1028-1037.	0.3	77
4	Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe. <i>Value in Health</i> , 1999, 2, 323-332.	0.3	63
5	Economic Evaluation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1993, 4, 173-186.	3.3	58
6	Economic consequences of ill-health for households in northern rural India. <i>BMC Health Services Research</i> , 2015, 15, 179.	2.2	30
7	Impact of Community-based Health Insurance on Access and Financial Protection: Evidence from Three Randomized Control Trials in Rural India. <i>Health Economics (United Kingdom)</i> , 2016, 25, 675-687.	1.7	28
8	Differences in Overweight and Obesity among Children from Migrant and Native Origin: The Role of Physical Activity, Dietary Intake, and Sleep Duration. <i>PLoS ONE</i> , 2015, 10, e0123672.	2.5	26
9	Economic evaluation and health care decision-making. <i>Health Policy</i> , 1996, 36, 215-229.	3.0	25
10	Combining a Budgetary-Impact Analysis and a Cost-Effectiveness Analysis Using Decision-Analytic Modelling Techniques. <i>Pharmacoeconomics</i> , 2002, 20, 855-867.	3.3	25
11	Assessment of biotechnology drugs: what are the issues?. <i>Health Policy</i> , 1999, 47, 255-274.	3.0	17
12	Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within?. <i>Value in Health</i> , 2017, 20, 240-243.	0.3	13
13	No cure, no pay: an acceptable way of financing fertility treatments?. <i>Health Policy</i> , 1989, 13, 239-249.	3.0	11
14	Intergration of economic appraisal and health care policy in a health insurance system; The Dutch case. <i>Social Science and Medicine</i> , 1994, 38, 1609-1614.	3.8	10
15	Handbook of Health Economics. <i>Journal of Health Economics</i> , 2001, 20, 855-879.	2.7	6
16	The Incorporation of Potential Confounding Variables in Markov Models. <i>Pharmacoeconomics</i> , 2003, 21, 941-950.	3.3	6
17	The Impact of Healthcare Reform in The Netherlands. <i>Pharmacoeconomics</i> , 2004, 22, 65-71.	3.3	2